

Atomo and NG Biotech expand COVID-19 partnership

10 June 2020 | News | By Manbeena Chawla

Atomo secures exclusive rights for Australia, New Zealand and South East Asia



Australian firm Atomo Diagnostics Limited is pleased to announce it has expanded its existing COVID-19 rapid test partnership with France based NG Biotech, SAS (**NG Biotech**), which was announced to ASX on 14 April 2020 in Atomo's Second Supplementary Prospectus (**Second Supplementary Prospectus**).

Under Atomo's existing binding supply agreement with NG Biotech referenced in the Second Supplementary Prospectus, Atomo has been supplying NG Biotech with its award-winning Galileo rapid test device for use in NG Biotech's blood-based rapid antibody IgG/IgM COVID19 test (the **COVID-19 antibody test**) which is branded 'NG Test IgG / IgM COVID19' when sold by NG Biotech in Europe. To date, NG Biotech has ordered in excess of 1.5 million Galileo devices from Atomo for use in NG Biotech's COVID-19 antibody test in France.

Under the expansion of the Atomo NG Biotech partnership, Atomo now has exclusive rights to market and distribute, as the listed manufacturer, the COVID-19 antibody test in Australia and New Zealand and a number of countries in South East Asia, subject to obtaining the required regulatory approvals in each jurisdiction, under the brand 'AtomoRapidTM COVID-19 (IgG/IgM)'.

At present, the period of exclusivity has not been specified (ie. it is not currently limited) and Atomo and NG Biotech are continuing to negotiate a definitive long term supply agreement. The pricing arrangements with NG Biotech are limited to a price payable per unit only and do not include any licence fees or royalties.

The exclusive rights arrangement for Australia, New Zealand and a number of South-East Asian countries is strategically important for Atomo as it repositions Atomo as a listed manufacturer of COVID-19 tests, building on its foundation of being the only manufacturer of a TGA approved Class 4 Self-Test in Australia, listed as the 'Atomo HIV Self-Test' on the *Australian Register of Therapeutic Goods (ARTG)*.